The Phase 2 study is designed to address regulatory approval considerations by comparing bioavailability and pharmacokinetics of NS002 against ...
Get the latest on Atea Pharmaceuticals’ Q3 2025 earnings, HCV Phase III progress, hepatitis E pipeline expansion, and key financial updates.
If you haven’t done so already, we encourage you to determine your short- and long-term career goals to identify your postdoc training needs. Creating an IDP is a great way to do this, and when you’re ...
Hosted on MSN
The final phase of the Interstate Improvement Project is starting this month, according to a GDOT release.
The whole project is expected to be complete in Fall 2029. The project started in 2017. Schumer offers plan to end shutdown on Senate floor NCAA finds 6 players from 3 schools involved in fixing games ...
Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for ...
KUALA LUMPUR, Oct 22 (Reuters) - The development of a 2,000-megawatt offshore wind energy project linking Vietnam, Malaysia, and Singapore is expected to complete its first phase by 2034, Malaysia's ...
In the heart of Provence, Southern France, the world's largest fusion energy experiment, which could be a step towards unlimited energy, has quietly entered perhaps the most critical stage yet. The ...
WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for ...
A new development in Rochester, known as The Ridge phase 2, is planned to include housing, commercial buildings, and a hospital emergency department. Developers are seeking a permit recommendation ...
WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies ...
CAL101 is a first-in-class monoclonal antibody targeting S100A4, a damage-associated molecular pattern (DAMP) protein associated with serious and life-threatening fibrotic disorders Phase 2 AURORA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback